As per the trusted sources, at the times when Bristol Myers Squibb and bluebird bio got FDA approval in March for their multiple myeloma CAR-T drug Abecma, the industry people were aware that the competitor from Legend Biotech and J&J wasn’t too far behind. Now that company is in the fast lane of the FDA.
J&J and Legend’s launched ciltacabtagene autoleucel, also known as cilta-cel, was also approved by the FDA on November 29, the previous year. Further, another drug by them, which is BCMA-directed CAR-T therapy, is also waiting for heads up by the FDA with the refractory or relapsed multiple myeloma.
Moreover, it is totally possible that the study data could make that happen, which just gained attention from the experts in the field of cancer. As per the reports, an expert on myeloma treatment who has tried all the three therapies in the past stated that he was impressed by the deep and durable treatment caused by the therapy. However, the J&J drug is more toxic, as stated by the experts, so they are testing it on fitter patients.